IL-7 armed binary CAR T cell strategy to augment potency against solid tumors.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Engineering

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for B-cell malignancies but faces challenges in solid tumors.
• Relapse in CAR T cell therapy often results from antigen loss and poor T cell persistence.
• Solid tumors present unique barriers including antigen heterogeneity and immune suppression, limiting CAR T cell efficacy.

Purpose of the Study:

• To develop a dual CAR T cell strategy targeting both PSCA and MUC1 to address antigen heterogeneity in solid tumors.
• To enhance T cell persistence and anti-tumor activity within the tumor microenvironment.
• To evaluate the efficacy of this binary CAR T cell approach in a preclinical pancreatic cancer model.

Main Methods:

• Engineering T cells with independent CARs targeting PSCA and MUC1.
• Co-expression of transgenic IL-7 cytokine and receptor (IL-7Rα) to promote localized T cell persistence.
• Assessment of the dual CAR T cell strategy's potency and durability in a pancreatic tumor model.

Main Results:

• The dual CAR T cell strategy effectively targeted both PSCA and MUC1 antigens.
• Engineered T cells exhibited enhanced persistence and localized anti-tumor activity.
• Demonstrated potent and durable antitumor effects in the pancreatic tumor model.

Conclusions:

• A dual CAR T cell strategy targeting PSCA and MUC1, combined with IL-7/IL-7Rα co-expression, offers a promising approach for solid tumors.
• This binary strategy effectively overcomes antigen heterogeneity and enhances T cell longevity.
• The findings support the potential of this enhanced CAR T cell therapy for pancreatic cancer treatment.